<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immutep Ltd — News on 6ix</title>
<link>https://6ix.com/company/immutep-ltd</link>
<description>Latest news and press releases for Immutep Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immutep-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683665b478dffbe2df15da54.webp</url>
<title>Immutep Ltd</title>
<link>https://6ix.com/company/immutep-ltd</link>
</image>
<item>
<title>Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-4</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-4</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States). The accepted abstract, titled “Impact of eft</description>
</item>
<item>
<title>Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA’s Orphan Drug Designation program is desi</description>
</item>
<item>
<title>Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-receives-fda-odd-for-efti-in-soft-tissue-sarcoma</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-receives-fda-odd-for-efti-in-soft-tissue-sarcoma</guid>
<pubDate>Wed, 15 Apr 2026 03:47:04 GMT</pubDate>
<description>Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma</description>
</item>
<item>
<title>Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-reports-progress-from-phase-i-study-of-lag-3-agonist-for-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-reports-progress-from-phase-i-study-of-lag-3-agonist-for-autoimmune-diseases</guid>
<pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
<description>Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blin</description>
</item>
<item>
<title>Update on Phase I Study of IMP761 for Autoimmune Diseases</title>
<link>https://6ix.com/company/immutep-ltd/news/update-on-phase-i-study-of-imp761-for-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/update-on-phase-i-study-of-imp761-for-autoimmune-diseases</guid>
<pubDate>Thu, 19 Mar 2026 01:41:06 GMT</pubDate>
<description>Update on Phase I Study of IMP761 for Autoimmune Diseases</description>
</item>
<item>
<title>TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis</title>
<link>https://6ix.com/company/immutep-ltd/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-66</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-66</guid>
<pubDate>Fri, 13 Mar 2026 12:00:00 GMT</pubDate>
<description>Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned in</description>
</item>
<item>
<title>TACTI-004 to be discontinued following futility analysis</title>
<link>https://6ix.com/company/immutep-ltd/news/tacti-004-to-be-discontinued-following-futility-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/tacti-004-to-be-discontinued-following-futility-analysis</guid>
<pubDate>Fri, 13 Mar 2026 02:18:04 GMT</pubDate>
<description>TACTI-004 to be discontinued following futility analysis</description>
</item>
<item>
<title>Reinstatement to Quotation</title>
<link>https://6ix.com/company/immutep-ltd/news/reinstatement-to-quotation-1</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/reinstatement-to-quotation-1</guid>
<pubDate>Fri, 13 Mar 2026 02:18:04 GMT</pubDate>
<description>Reinstatement to Quotation</description>
</item>
<item>
<title>Suspension from Quotation</title>
<link>https://6ix.com/company/immutep-ltd/news/suspension-from-quotation</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/suspension-from-quotation</guid>
<pubDate>Wed, 11 Mar 2026 03:19:03 GMT</pubDate>
<description>Suspension from Quotation</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/immutep-ltd/news/trading-halt-69</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/trading-halt-69</guid>
<pubDate>Fri, 06 Mar 2026 11:56:03 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/immutep-ltd/news/half-yearly-report-and-accounts-41</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/half-yearly-report-and-accounts-41</guid>
<pubDate>Wed, 25 Feb 2026 03:28:21 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-achieves-50-enrolment-global-130000681</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-achieves-50-enrolment-global-130000681</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases,</description>
</item>
<item>
<title>Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-achieves-50percent-enrolment-in-global-tacti-004-1l-nsclc</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-achieves-50percent-enrolment-in-global-tacti-004-1l-nsclc</guid>
<pubDate>Fri, 06 Feb 2026 02:40:13 GMT</pubDate>
<description>Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC</description>
</item>
<item>
<title>Immutep Quarterly Activities Report Q2 FY26</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-quarterly-activities-report-q2-130000702</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-quarterly-activities-report-q2-130000702</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of eftiStrong operational progress reported for TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-</description>
</item>
<item>
<title>Immutep Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-quarterly-activities-report-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-quarterly-activities-report-and-appendix-4c</guid>
<pubDate>Thu, 29 Jan 2026 05:57:03 GMT</pubDate>
<description>Immutep Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-announces-positive-imp761-first-130000273</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-announces-positive-imp761-first-130000273</guid>
<pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
<description>Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profileSubstantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesGiven encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical</description>
</item>
<item>
<title>Positive Update on IMP761 Phase 1</title>
<link>https://6ix.com/company/immutep-ltd/news/positive-update-on-imp761-phase-1</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/positive-update-on-imp761-phase-1</guid>
<pubDate>Mon, 22 Dec 2025 02:46:07 GMT</pubDate>
<description>Positive Update on IMP761 Phase 1</description>
</item>
<item>
<title>Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-announces-strong-operational-progress-130000779</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-announces-strong-operational-progress-130000779</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I</description>
</item>
<item>
<title>TACTI-004 phase III trial enrolment continues at robust pace</title>
<link>https://6ix.com/company/immutep-ltd/news/tacti-004-phase-iii-trial-enrolment-continues-at-robust-pace</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/tacti-004-phase-iii-trial-enrolment-continues-at-robust-pace</guid>
<pubDate>Tue, 16 Dec 2025 02:55:10 GMT</pubDate>
<description>TACTI-004 phase III trial enrolment continues at robust pace</description>
</item>
<item>
<title>Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa</title>
<link>https://6ix.com/company/immutep-ltd/news/immutep-dr-reddy-enters-strategic-130000064</link>
<guid isPermaLink="true">https://6ix.com/company/immutep-ltd/news/immutep-dr-reddy-enters-strategic-130000064</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE</description>
</item>
</channel>
</rss>